The Science and Economics of GLP-1s: Strategies for Healthcare Leaders
GLP-1s are transforming employee benefits expectations – and driving up plan costs. In this episode of the ASHHRA Podcast, RxBenefits Director of Clinical Services Langley Kyle dives deep into the complex landscape of this medication class.
This discussion moves beyond the GLP-1 hype to explore the clinical science and economic realities facing healthcare organizations today. Gain critical insights on evaluating utilization, forecasting trends, and building a pharmacy benefits plan that balances patient outcomes with financial sustainability.
Learn how to effectively manage your GLP-1 strategy without compromising care.
We’re happy to connect with you or your benefits advisor to discuss how your organization can stay prepared in this ever-changing landscape.
You Might Also Enjoy
The Battle Over 340B Drug Pricing (Part 2)
The Battle Over 340B Drug Pricing (Part 2) Explore the complexities and upcoming changes to 340B with RxBenefits and the…
Why HR Leaders Should Care About 340B
Why HR Leaders Should Care About 340B As the second-largest federal drug program in the U.S., the 340B program plays…
